KAYLA DAVISON: Open Payments
NPI 1447638895 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$387 in 18 payments from 13 companies in 2025. Trend: 2023 $234 · 2024 $328 · 2025 $387
Food & beverage: $387
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $136 |
| Astellas Pharma US Inc | 1 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Ascensia Diabetes Care Us Inc. | 1 | $21 |
| Medtronic, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Novo Nordisk Inc | 1 | $18 |
| SANOFI-AVENTIS U.S. LLC | 1 | $18 |
| Gilead Sciences, Inc. | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16 |
Products named: BREZTRI, AIRSUPRA, Veozah, OPSUMIT, SYMPLICITY G3, REXULTI, Ozempic, TZIELD.
Industry payments across NE — which companies pay providers there.
